Thus, the beneficial effects of PPAR agonists in APL may be derived from not only the direct lowering of blood lipids but also a potential inhibition of TRIB3 expression; this concept needs further clarification. The gene discussed is PPARA; the disease is acute promyelocytic leukemia.